AlfuzosinCAS# 81403-80-7 |
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
- Medetomidine
Catalog No.:BCC1736
CAS No.:86347-14-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 81403-80-7 | SDF | Download SDF |
| PubChem ID | 2092 | Appearance | Powder |
| Formula | C19H27N5O4 | M.Wt | 389.45 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (128.39 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide | ||
| SMILES | CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC | ||
| Standard InChIKey | WNMJYKCGWZFFKR-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Alfuzosin Dilution Calculator
Alfuzosin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5677 mL | 12.8386 mL | 25.6772 mL | 51.3545 mL | 64.1931 mL |
| 5 mM | 0.5135 mL | 2.5677 mL | 5.1354 mL | 10.2709 mL | 12.8386 mL |
| 10 mM | 0.2568 mL | 1.2839 mL | 2.5677 mL | 5.1354 mL | 6.4193 mL |
| 50 mM | 0.0514 mL | 0.2568 mL | 0.5135 mL | 1.0271 mL | 1.2839 mL |
| 100 mM | 0.0257 mL | 0.1284 mL | 0.2568 mL | 0.5135 mL | 0.6419 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Alfuzosin is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
- Alfuzosin HCl
Catalog No.:BCC2494
CAS No.:81403-68-1
- Acetylvalerenolic acid
Catalog No.:BCC8112
CAS No.:81397-67-3
- Fmoc-His(Boc)-OH.CHA
Catalog No.:BCC2595
CAS No.:81379-52-4
- Seglitide
Catalog No.:BCC7191
CAS No.:81377-02-8
- Momordicoside G
Catalog No.:BCN4349
CAS No.:81371-54-2
- Momordicoside K
Catalog No.:BCN3272
CAS No.:81348-84-7
- Momordicoside L
Catalog No.:BCN3274
CAS No.:81348-83-6
- Momordicoside F1
Catalog No.:BCN3273
CAS No.:81348-81-4
- Cyclo(Tyr-Hpro)
Catalog No.:BCN2424
CAS No.:813461-21-1
- Schisandrin C epoxide
Catalog No.:BCN3744
CAS No.:81345-36-0
- Amisulpride hydrochloride
Catalog No.:BCC4252
CAS No.:81342-13-4
- D-AP7
Catalog No.:BCC6559
CAS No.:81338-23-0
- EHNA hydrochloride
Catalog No.:BCC6996
CAS No.:81408-49-3
- Cabergoline
Catalog No.:BCC5276
CAS No.:81409-90-7
- Sanggenone D
Catalog No.:BCN1194
CAS No.:81422-93-7
- 8-Acetoxypinoresinol
Catalog No.:BCN2161
CAS No.:81426-14-4
- 8-Hydroxypinoresinol
Catalog No.:BCN3389
CAS No.:81426-17-7
- (-)-Pinoresinol
Catalog No.:BCN3254
CAS No.:81446-29-9
- Taxagifine
Catalog No.:BCN6949
CAS No.:81489-69-2
- 1-Hydroxypinoresinol 1-O-glucoside
Catalog No.:BCN7019
CAS No.:81495-71-8
- alpha-Dihydroartemisinin
Catalog No.:BCN2627
CAS No.:81496-81-3
- Nafamostat
Catalog No.:BCC4187
CAS No.:81525-10-2
- Forsythoside B
Catalog No.:BCN1205
CAS No.:81525-13-5
- 2-Pentadecenedioic acid
Catalog No.:BCN3666
CAS No.:81588-35-4
The effect of alfuzosin on renal resistive index, urinary electrolytes and beta2 microglobulin levels and TGF beta-1 levels of kidney tissue in rats with unilateral ureteropelvic junction obstruction.[Pubmed:27402370]
Ren Fail. 2016 Sep;38(8):1283-90.
BACKGROUND: In this study, it was aimed to determine the effects of Alfuzosin on experimentally generated unilateral partial ureteropelvic junction obstruction (UPO) in rats. MATERIALS AND METHODS: Thirty Long-Evans rats were randomly allocated into five groups. In control group (C), nothing was performed; in group Sham (S) only laparotomy was done; in Alfuzosin group (A) only Alfuzosin was administered for two weeks (10 mg/kg/day p.o.) without any surgery; in UPO group, unilateral UP junction obstruction was produced; and in the Group UPT (ureteropelvic obstruction + treatment), Alfuzosin was administered for two weeks (10 mg/kg/day p.o.) in addition to UPO production. Renal pelvic anteroposterior diameters were determined with ultrasonography (USG) and renal arterial resistivity indexes by color Doppler USG. Urine was collected both at the beginning and at the end of the experiment for 24 h in all the groups and at the end of the experiment, blood samples were obtained. Blood and urine electrolytes and TGF-beta1, urine density, urine beta2 microglobulin levels were determined. Renal tissue samples harvested from all of the rats were histopathologically evaluated. Results were determined using one-way ANOVA t-test; p < 0.05 was accepted as significant. RESULTS: Urine density in the UPT group was lower with respect to UPO group and blood electrolytes were preserved as close to normal (p < 0.05). In the UPT group, urine TGF-beta1 and blood TGF-beta1, blood beta2 microglobulin levels and histopathologic damage scores were lower compared to the UPO group (p < 0.05). CONCLUSION: It is shown in this experimental unilateral partial UPO model that Alfuzosin treatment prevents obstructive renal damage.
Highly Sensitive Fluorescence Methods for the Determination of Alfuzosin, Doxazosin, Terazosin and Prazosin in Pharmaceutical Formulations, Plasma and Urine.[Pubmed:27396658]
Anal Sci. 2016;32(7):763-8.
Polymeric ionic liquid-coated magnetic nanoparticles have been successfully prepared as adsorbents for the magnetic solid-phase extraction of four drugs, namely Alfuzosin, doxazosin, terazosin and prazosin, from pharmaceutical preparations, urine samples and plasma samples. The four drugs were detected by fluorescence spectrophotometer. Several extraction parameters, including the pH of the solution; the type, ratio and volume of the desorbing reagent; the amount of adsorbent; the time of the extraction and desorption processes; and the addition of NaCl, were investigated and optimized. Linear responses were determined for the four drugs in the concentration range of 0.5 - 45 ng mL(-1). The limit of detection values for Alfuzosin, doxazosin, terazosin and prazosin, which were defined as three times the standard deviation of a blank sample, were determined to be 0.035, 0.034, 0.027 and 0.028 ng mL(-1) (n = 11), respectively. Furthermore, this new method gave preconcentration factors of 114.5, 111.3, 111.1 and 108.5 for these four drugs.
Prophylactic effects of alpha-blockers, Tamsulosin and Alfuzosin, on postoperative urinary retention in male patients undergoing urologic surgery under spinal anaesthesia.[Pubmed:27286124]
Int Braz J Urol. 2016 May-Jun;42(3):578-84.
PURPOSE: Postoperative urinary retention (POUR) is one of the most common complications after surgical procedures under spinal anaesthesia. Recent studies have shown the beneficial effects of alpha-adrenergic blockers in preventing POUR. The aim of this prospective study was to investigate and compare the prophylactic effects of tamsulosin and Alfuzosin on POUR after urologic surgical procedures under spinal anaesthesia. MATERIALS AND METHODS: A total of 180 males who underwent elective urologic surgery were included in this study. The patients were randomly allocated into three Groups. The Group I received placebo. Patients in Group II were given 0.4mg of tamsulosin orally 14 and 2 hours before surgery. Patients in Group III were given 10mg of Alfuzosin ER orally 10 and 2 hours before surgery. All patients were closely followed for 24 hours postoperatively and their episodes of urinary retentions were recorded. RESULTS: There were 60 patients in each Group. Their mean age was 35.95+/-15.16 years. Fifteen patients in Group I (25%), 3 patients in Group II (5%) and 4 patients in Group III (6.7%) required catheterization because of urinary retention. In tamsulosin group and Alfuzosin group, there were a significantly lower proportion of patients with POUR compared with the placebo Group (p=0.002 and p=0.006). The beneficial effects of tamsulosin and Alfuzosin on POUR were similar between both Groups (p=0.697). CONCLUSION: This study suggests that the use of prophylactic tamsulosin or Alfuzosin can reduce the incidence of urinary retention and the need for catheterization after urologic surgical procedures under spinal anaesthesia.
Utility of Hantzsch reaction for development of highly sensitive spectrofluorimetric method for determination of alfuzosin and terazosin in bulk, dosage forms and human plasma.[Pubmed:28303653]
Luminescence. 2017 Sep;32(6):1066-1071.
A highly sensitive, cheap, simple and accurate spectrofluorimetric method has been developed and validated for the determination of Alfuzosin hydrochloride and terazosin hydrochloride in their pharmaceutical dosage forms and in human plasma. The developed method is based on the reaction of the primary amine moiety in the studied drugs with acetylacetone and formaldehyde according to the Hantzsch reaction, producing yellow fluorescent products that can be measured spectrofluorimetrically at 480 nm after excitation at 415 nm. Different experimental parameters affecting the development and stability of the reaction products were carefully studied and optimized. The fluorescence-concentration plots of Alfuzosin and terazosin were rectilinear over a concentration range of 70-900 ng ml(-1) , with quantitation limits 27.1 and 32.2 ng ml(-1) for Alfuzosin and terazosin, respectively. The proposed method was validated according to ICH guidelines and successfully applied to the analysis of the investigated drugs in dosage forms, content uniformity test and spiked human plasma with high accuracy.
